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ABSTRACT
An unusual emm53, T-28 ⁄T-non-typeable, iMLSB
phenotype clone represented a substantial pro-
portion (28.6%) of invasive erythromycin-resist-
ant group A streptococcus (GAS) isolates in the
Czech Republic during 2003. Clonal analysis of
emm53 isolates between 2001 and 2004 revealed
four pulsed-ﬁeld gel electrophoresis (PFGE) pat-
terns and two emm subtypes. Isolates produced
identical PFGE patterns regardless of their inva-
siveness and ⁄ or tetracycline resistance. Multilocus
sequence typing classiﬁed all isolates as ST340. An
ST5 (emm83) isolate, a potential ancestor of ST340,
was isolated in the Czech Republic from an
impetigo patient in 1988. The Czech emm53 ⁄ ST340
isolates shared only three of seven alleles with the
original Lanceﬁeld emm53 ⁄ ST11 isolate.
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During the period 2001–2005, 215 invasive isolates
of group A streptococcus (GAS) (one per patient)
were obtained from 34 hospitals throughout the
Czech Republic, of which ten (4.7% of the total)
belonged to type emm53. The highest proportion
of emm53 isolates was detected in 2003 (six of 59
isolates; 10.2%). Most emm53 isolates were resist-
ant to erythromycin (MIC range 8–64 mg ⁄L), and
some were also resistant to tetracycline (MIC
range 16–32 mg ⁄L). The overall rate of macrolide
resistance among GAS isolates from invasive
disease, based on data from 2003 to 2005, was
16.6% (27 of 162). Four (28.6%) invasive macro-
lide-resistant isolates were type emm53 during
2003. The prevalent emm types among all invasive
GAS isolates in 2001–2005 from the Czech Re-
public were emm1, emm81, emm28, emm53, emm3
and emm66, while emm28, emm53, emm117, emm4
and emm78 were the most common types among
macrolide-resistant invasive GAS isolates.
The age of patients ranged from 11 days to
97 years (11–58 years for emm53 isolates), and the
disease presentation varied from bacteraemia or
arthritis to more serious presentations, e.g., nec-
rotising fasciitis or septic shock. Details of the
isolates from 13 cases are summarised in Table 1.
Details of the surveillance methods [1,2] and
overall macrolide resistance trends [3] have been
described previously. The emm53 type accounted
for 4.0% (ten of 248) of non-invasive isolates from
patients who presented with sore throat or mild
skin lesions during 2001–2002. Three randomly
selected non-invasive emm53 isolates were added
to the invasive group for comparison.
Thus, in total, 13 epidemiologically unlinked
emm53 isolates were characterised by classical
serotyping (T, SOF and M), emm sequence-based
typing, pulsed-ﬁeld gel electrophoresis (PFGE)
and multilocus sequence typing (MLST), tested
for resistance to erythromycin and tetracycline,
and subjected to MLSB resistance phenotyping. T,
SOF and M typing were performed by standard
methods [4], while emm typing was performed
according to Whatmore et al. [5], as described
by Beall (http://www.cdc.gov/ncidod/biotech/
strep/protocols.htm), using primer 1 (TATT
(C ⁄G)GCTTAGAAAATTAA) and primer 2 (GCA-
AGTTCTTCAGCTTGTTT), with emmseq2 (TAT-
TCGCTTAGAAAATTAAAAACAGG) as the seq-
uencing primer. PFGEwas performed by the rapid
method of Benson and Ferrieri [6], with the follow-
ing minor modiﬁcations: SmaI digestion for 3 h;
6.0 V ⁄ cm for 10–35 s; 14C; 0.5 · TBE buffer exten-
dedrange (Bio-Rad); total timeof20 h.Visual assig-
nation of PFGE types was according to published
recommendations [7]. MLST was carried out as
described previously (http://spyogenes.mlst.net).
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Resistance phenotypingwas based on the standard
double-disk diffusion method [8], while resistance
to erythromycin and tetracycline was determined
by MIC tests [9].
All 13 isolates studiedwere either T-28 or T-non-
typeable, which is an unusual ﬁnding, as emm53 is
normally associated with the T-3 ⁄ 13 ⁄B3264
complex. All 13 isolates were also SOF-negative
and M-non-typeable, but were divided by emm
sequence-based analysis into two groups that
differed from each other by a single base at
position 22 (starting at the end of the signal
sequence), i.e., G for emm53.2 and A for emm53.6.
PFGE yielded a single type, with four sub-
types differing by a maximum of four bands.
Although the results suggested an association
between emm type and PFGE proﬁle at the clo-
nal group level, no correlation was observed
between distinct PFGE genotypes and emm
subtypes. Identical proﬁles were observed for both
invasive and non-invasive isolates; tetracycline-
resistant and tetracycline-susceptible isolates also
shared identical proﬁles. The characterisation of
the 13 emm53 isolates is summarised in Table 1.
All of the study isolates were classiﬁed as ST340.
Based on an eBURST analysis of the worldwide
GAS database (http://spyogenes.mlst.net/sql/
eburst_all.asp), ST5 was proposed as a possible
ancestor of the ST340 strain. ST5, ST103, ST205 and
ST340 are the sole members of the same clonal
complex, deﬁned as sharing six of seven alleles.
Using a less stringently deﬁned eBURST group
(sharing ﬁve of seven alleles), ST340 belongs to the
same group, togetherwith 50 other sequence types.
A similar increase in type emm53 isolates among
invasive GAS isolates was observed in Finland in
1998 [10]; however, macrolide resistance was not
tested in this previous study. One of the emm53
variants described in the Finnish study corres-
ponds to subtype emm53.2 identiﬁed in the present
study (T. Siljander, personal communication). A T-
8 ⁄ 25 ⁄ Imp19 ST340 isolate of unknown emm type
was also found in Norway in 2002 (http://spyo-
genes.mlst.net/). Based on published data, the
emm53 type has not been detected to date among
erythromycin-resistant isolates in other European
countries [11–14]. It is not known whether the
incidence of this type is locally speciﬁc.
An emm83-ST5 strain was isolated in the
Czech Republic from a patient with impetigo
in 1988, and this may be a possible ancestor of
the ST340 strain; the most recently detected mem-
ber of this strain was a non-invasive skin isolate in
2002, but no other emm83 isolates were detected
among invasive GAS isolates during 1994 – 2005.
No emm53 isolates were detected among invasive
GAS isolates during 1994 – 2000 (total n = 108).
The incidence of emm53 isolates declined in 2004,
compared with 2003, when emm28 became the
predominant type among erythromycin-resistant
invasive isolates from the Czech Republic. No
isolate of type emm53 was observed among inva-
sive isolates in 2005. Further analysis of both
invasive and non-invasive streptococcal isolates is
particularly important in view of the development
of a safe and effective anti-streptococcal vaccine.
More extensive and statistically valid characteri-
sation studies are required.
This is the ﬁrst report of macrolide-resistant
emm53 isolates. All the emm53 GAS isolates
from the Czech Republic belonged to the ST340
clone. eBURST analysis revealed that the emm53-
ST340 clone from the Czech Republic is related
more closely to emm83-ST5 isolates than to the
Table 1. Characterisation of 13 emm53groupAstreptococcal isolates from theCzechRepublic thatwere included in the study
Isolate
number
Year ⁄district
of isolation Invasiveness (source) T type
emm
subtype
PFGE
pattern Erythromycin Tetracycline Phenotypeb
1 2001 ⁄BN NI ⁄ erythema (skin) 28 53.6 A1 R R iMLSB
2 2001 ⁄VY I ⁄ shock, necrotising fasciitis (blood) NT 53.6 A1 R R iMLSB
3 2002 ⁄BN NI ⁄mild lesion (skin) NT 53.6 A1 R R iMLSB
4 2002 ⁄BV NI ⁄ erythema (skin) NT 53.6 A1 R R iMLSB
5 2002 ⁄ ST I ⁄ arthritis (joint ﬂuid) 28 53.6 A1 R R iMLSB
6a 2003 ⁄VY I ⁄ bacteraemia (blood) NT 53.2 A2 S R S
7a 2003 ⁄HB I ⁄ bacteraemia (blood) 28 53.2 A3 S R S
8a 2003 ⁄KA I ⁄ bacteraemia (blood) NT 53.2 A1 R S iMLSB
9a 2003 ⁄TV I ⁄ cellulitis (deep tissue) NT 53.6 A4 R R iMLSB
10a 2003 ⁄KN I ⁄ cellulitis (deep tissue) NT 53.2 A1 R S iMLSB
11a 2003 ⁄KN I ⁄ necrotising fasciitis (deep tissue) NT 53.6 A1 R R iMLSB
12a 2004 ⁄PE I ⁄ cellulitis (deep tissue) NT 53.6 A4 R R iMLSB
13a 2004 ⁄CB I ⁄ necrotising fasciitis (deep tissue) NT 53.6 A4 R R iMLSB
I, invasive; NI, non-invasive; NT, non-typeable; PFGE, pulsed-ﬁeld gel electrophoresis; S, sensitive; R, resistant; iMLSB, inducible macrolide resistance.
aIsolates included in the Strep-EURO programme.
bMacrolide resistance phenotype.
444 Clinical Microbiology and Infection, Volume 13 Number 4, April 2007
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 430–456
Lanceﬁeld collection emm53-ST11 isolate. The new
subtypes and sequence types from this study have
been submitted to the central worldwide database.
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Climate and genotypes of Pneumocystis
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ABSTRACT
This study explored whether seasonal and ⁄ or
climatic factors inﬂuenced detection of speciﬁc
genotypes of Pneumocystis jirovecii. Between 1989
and 2001, 155 isolates of P. jirovecii were obtained
from patients undergoing bronchoscopic alveolar
lavage. For each isolate, the month and climatic
conditions were noted. Genotypes of P. jirovecii
were distinguished by polymorphisms in the
mitochondrial large-subunit rRNA gene. There
were monthly and seasonal variations in the
frequency of detection of mixed genotypes
(p 0.018 and p 0.031, respectively) and genotype
2 (p 0.029 and p 0.086, respectively). There was no
association between month ⁄ season and genotypes
1, 3 and 4, or between monthly temperature or
rainfall and any genotype.
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